Recent Updates — HMDCF

HUTCHMED (China) Limited announced the closing of an exclusive development and license agreement with a subsidiary of GSK plc for its KRAS-EGFR antibody conjugate therapy candidate, HMPL-A830. The deal grants GSK worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan to develop and commercialize the drug following the completion of customary closing conditions, including antitrust regulatory reviews. HUTCHMED Limited retains responsibility for the global Phase I development program, while GSK will manage subsequent clinical development and commercialization in its territory. Under the agreement terms, HUTCHMED expects to receive a US$110 million upfront payment shortly upon closing. The company may also receive additional development, regulatory, and commercial milestone payments totaling up to US$1.185 billion, along with tiered royalties on annual net sales. This transaction represents a significant strategic partnership for the biopharmaceutical company, which focuses on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases.

HUTCHMED (China) Limited announced that clinical data for its oncology portfolio will be presented at the ESMO Congress 2026 in Madrid. The company highlighted late-breaking abstracts from two positive Phase III studies of the savolitinib and osimertinib combination for non-small cell lung cancer, including the global SAFFRON study and the China-based SANOVO study. Additional data on fruquintinib, surufatinib, and other combinations will be presented in poster sessions and symposia throughout October 2026. HUTCHMED is a biopharmaceutical company focused on the discovery and commercialization of targeted cancer therapies.

HUTCHMED (China) Limited announced positive high-level results from the global Phase III SAFFRON trial, demonstrating that ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) provided statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to platinum-based chemotherapy. The study enrolled 338 patients with MET-driven EGFR-mutated non-small cell lung cancer who had progressed on prior TAGRISSO treatment. These findings reinforce the combination's efficacy and support global regulatory registration efforts for this biomarker-directed therapy. HUTCHMED is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.